Here are the 10-K annual reports from Catalyst Pharmaceutical Inc. (CPRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPRX filings page.
Catalyst Pharmaceuticals, Inc. filed Amendment No. 1 to its 2025 annual report to include Part III information on directors, executive officers, corporate governance, executive compensation, security ownership, and auditor fees. The company confirms the amendment adds no new financial statements and does not change previously reported results.
The filing details 2025 pay-versus-performance data, showing net product revenue of $588.8 million and net income of $214.3 million, and discloses a 2025 CEO total compensation of $8.18 million with a CEO pay ratio of 26:1. It also describes the 2018 Stock Incentive Plan, including outstanding stock options and restricted stock units, and outlines governance policies such as the code of ethics, insider trading policy, and board committee structures.
Catalyst Pharmaceuticals describes a commercial-stage rare disease business built around three neurology products: FIRDAPSE for Lambert‑Eaton myasthenic syndrome (LEMS), AGAMREE for Duchenne muscular dystrophy (DMD), and FYCOMPA for epilepsy. The company emphasizes patient-support infrastructure through its Catalyst Pathways program and extensive field, medical, and reimbursement teams.
Catalyst reports approximately $709.2 million in cash and cash equivalents as of December 31, 2025 and believes this supports operations for at least the next 12 months. A share repurchase program authorizes up to $200 million of buybacks through December 31, 2026; by February 23, 2026, it had repurchased 1,740,713 shares for about $39.9 million.
The filing details settlements with several generic challengers to FIRDAPSE and ongoing Paragraph IV litigation with Hetero covering patents expiring between 2032 and 2037, alongside upcoming loss of orphan exclusivity in November 2025. For AGAMREE, Catalyst outlines a North American license with Santhera, including a $75 million upfront payment, a $36 million FDA‑approval milestone, and additional sales‑based milestones after 2025 net product revenue exceeded $100 million. FYCOMPA’s main patents expire by July 1, 2026, and multiple generics are already on the market, leading Catalyst to cease active marketing after December 31, 2025 while continuing to sell both tablets and oral suspension.